

GOAL

Step 1: Select Appropriate RASS

DCMC PICU Sedation & Delirium Management

	Richmond A	gitation Se	dation Scale (RASS)	Ok to assess for	Appropriate to paralyze?	
Score		Description delirium with CAPD?				
+4	Combative	Violent, im	mediate danger to staff			
+3	Very Agitated	Pulls at or	removes tubes, aggressive			
+2	Agitated	Frequent n ventilator	on-purposeful movements, fights			
+1	Restless		pprehensive but movements not or vigorous	Assess for delirium each shift with CAPD for	No! Administer sedation first	
0	Alert & Calm	RASS ≥ -3			to target RASS - 4	
-1	Drowsy	Responds	Not fully alert, sustained awakening to voice (eye opening & contact > 10 secs)			
-2	Light Sedation	to VOICE	Briefly awakens (not sustained) to voice (eye opening <10 secs)		ľ	
-3	Moderate Sedation		Movement or eye-opening to voice (no eye contact)			
-4	Deep Sedation	Responds only to TOUCH	No response to voice, but movement or eye opening to physical stimulation	Do not assess for delirium with CAPD for	Yes! If indicated, it would be appropriate to	
-5	Un-Arousable	No response paralysis	e to voice or physical stimulation -	RASS -4 or -5	RASS -4 or paralyze a	

	to ICU should be Non-Pharmacologic
)	screened for delirium using CAPD each shift (0000, 1200) Measures should be implemented for all patients
	CAPD >/= 9 is indicative of possible ICU delirium CAPD < 9 is negative for delirium
ı	
	Discuss score on daily rounds Assess patient for the following using BRAIN MAPS Ensure Preventative Non-Pharmacologic Measures are implemented
	Underlying Disease Introgenic Causes Optimize Environment
	Strong emphasis on Non-Pharmacologic Measures If No Resolution: Consider Pharmacologic Therapy

All patients admitted

Preventative

	BRAINMAPS: Common Causes of Delirium 4					
Potential Deliriogenic Factors		Need to Address / Recommendations				
В	B ring Oxygen	Hypoxemia Low Cardiac Output Anemia				
R Remove/Reduce Drugs		Anticholinergics (Diphenhydramine, Steroids, Opioids, BZD) Benzodiazepines Opioids				
A	<u>A</u> tmosphere	Sleep-wake cycle: Lights on/off schedule, Noise reduction, Provide Familiarity: Caregiver presence, Photos, Toys, Books ↓ Confusion: Glasses, hearing aids, Communication tools ↑ Rest: Cluster care, Minimize overnight interventions Minimize Fear: Utilize Child Life				
I	<u>I</u> nfection/ <u>I</u> mmobilization/ <u>I</u> nflammation	Infectious Workup Early Mobilization				
N	New Organ Dysfunction	Assess: CNS, CV, Pulm, Hepatic, Renal, Endocrine				
M	<u>M</u> etabolic Disturbance	Assess: CMP, Blood Gas				
Α	<u>A</u> wake	Normalize sleep/wake cycles				
P	P ain	Treat pain appropriately - assess for under or over treatment				
S <u>S</u> edation		Lighten sedation goals Avoid benzodiazepines as much as possible				

Non Pharmacologic Prevention & Management of Delirium

Initiate Early PT / OT

2: If RASS >/= -3: Complete CAPD Screen qShift

Step

- Normalize Sleep/ Wake Cycle: Create Lights on/off schedule, Noise reduction
- Provide Familiarity: Caregiver presence, Photos, Toys, Books
- Decrease Confusion: Glasses, hearing aids, communication tools
- Increase Rest: Cluster care, minimize overnight interventions
- Minimize Fear: Engage family in soothing, Utilize Child Life Services
- Family Engagement: help promote sleep mimic home sleep routine, quiet room, soothing music, turn off lights/TV at night/during nap time, earmuffs for infants

Pharmacologic Treatment of ICU Delirium

- Consider for delirium persistent after strict non-pharm
- Drug Class of Choice: Atypical antipsychotics
- Always use the lowest effective dose avoid risk of adverse effects associated with antipsychotics (metabolic, extrapyramidal, cardiac)
- Risperidone is PO drug of choice (see reverse for DOSING)
 - Liquid formulation and ease of dose titration
 - Lowest risk of QTc prolongation
- IM Olanzapine or IV haloperidol may be considered for emergencies only
- Assess baseline QTc & repeat q48-72 hrs after initiation or increase
- Dose should not be changed more frequently than every 48 hours
- If pharmacologic therapy was not beneficial, discontinue therapy and further optimize non-pharm measures, minimize iatrogenesis
- Assess ability to discontinue pharmacologic therapy after 5-7 days

Step 3: Assess BRAINMAPS & Manage Delirium

Risperidone Oral Liquid ^{5,6}					
Weight	Initial Dose	Dose Change Increment			
2.5-5 kg	0.1 mg qHS	0.1 mg BID, Max = 0.15 mg BID			
5.1-10 kg	0.2 mg qHS	0.2 mg BID, Max = 0.25 mg BID			
10.1-20 kg	0.3 mg qHS	0.3 mg BID, Max = 0.4 mg BID			
0.1-40 kg 0.4 mg qHS		0.4 mg BID, Max = 0.8 mg BID			
≥ 40.1 kg	0.5 mg qHS	0.5 mg BID, Max = 1 mg BID			

- < 20 kg: Doses > 1mg/day not associated with added benefit
- ≥ 20kg: Doses >2.5 mg/day not associated with added benefit

Monitoring Risperidone for ICU Delirium

- Baseline QTc and every 72 hours
- CAPD Trend
- Extrapyramidal symptoms

Dose Titration for Risperidone for ICU Delirium

- No more frequent than q48h increases
- May increase for no change in CAPD/ delirium symptoms (See Dosing Table)
- Dose reduce for side effects (see Monitoring)
- Discontinue if no improvement in delirium with increased dosing
- Weaning may be done over 48-72 hours if on low dosage; consult pharmacy if on high dosage

References

- Traube C, Silver G, Kearney J et al. Cornell Assessment of Pediatric Delirium: A Valid, Rapid, Observational Tool for Screening Delirium in the PICU. Critical Care Medicine. 2014; 42(3) 656-663.
- Silver G, Kearney J, Traube C, Hertzig M. Delirium screening anchored in child development: The Cornell Assessment for Pediatric Delirium. *Palliative and Supportive Care*. 2015; 13: 1005-1011.
- Meagher D, Morandi A, Inouye S, et al. Concordance between DSM-IV and DSM-5 criteria for delirium diagnosis in a pooled database of 768 prospectively evaluated patients using the delirium rating scale-revised-98. BMC Medicine. 2014; 12:164.
- Smith HA, Brink E, Fuchs DC, Wesley E, Pandharipande PP. Pediatric Delirium Monitoring and Management in the Pediatric Intensive Care Unit. Pediatr Clin North Am. 2013; 60(3): 741-760.
- Campbell C, Grey E, Munoz-Pareja J, Manasco K. An evaluation of risperidone dosing for children less than or equal to 2 years of age. Annals of Pharmacotherapy. 2020; 54 (5): 464-469.
- Capino A, Thomas A, Baylor S et al. Antipsychotic Use in the Prevention and treatment of Intensive Care Unit Delirium in Pediatric Patients. J Pediatr Pharmacol Ther. 2020; 25 (2): 81-95.

Disclaimer: This is a guidance document, modifications may be made on a case by case basis

DCMC Delirium Algorithm

adapted from CHOP and University of Missouri Women's and Children's Hospital's delirium protocols

Questions, Comments, Concerns:

cynthia.mccune1@ascension.org akwilson@ascension.org

Updated:

May 8, 2020



